Introduction
Breast cancer is one of the most frequent tumors among women in developed countries. Improvement in early diagnosis has increased the survival rates. Besides representing one of the cancers with the greatest advances in both understanding of the underlying causes of the disease and the development of new treatments in the last decades, breast cancer is still one of the most important causes of death in women in industrialized countries (Bonilla et al., 2001) .
Breast carcinomas show some distinctive characteristics that have implications in treatment strategies. One variety implies estrogen, since it is involved in the onset and progression of breast carcinomas (Sluyser, 1990) , and another important factor is the expression of the erbB-2 receptor which is overexpressed in 25 ± 40% of breast tumors overall (Bonilla et al., 2001; Salazar et al., 2001; Pegram et al., 1999) . These speci®c properties have played a critical role in the development of new strategies for treatment, such as hormone therapy or neutralizing antibodies to erbB-2.
Some studies have shown a better survival of women treated by hormone therapy with respect to the untreated. However, this therapy is more eective in ER-positive breast carcinomas. For instance, the selective estrogen receptor modulator raloxifene has shown to signi®cantly reduce the number of ERpositive tumors while this eect was not observed in the ER-negative ones (Fentiman, 2000) . As well, tamoxifen, the prototype of this kind of drugs, has demonstrated antiproliferative eects in metastatic breast cancer patients whose tumors expressed ER (Osborne, 1998) . On the other hand, although recently incorporated in the clinic, the use of neutralizing antibodies to erbB-2 has shown a limited ecacy with a 20 ± 25% rate of responses in erbB-2-overexpressing tumors (Salazar et al., 2001; Pegram et al., 1999) .
As a consequence of this relevance, breast cancer has been the target of many clinical trials for the last two decades and all these eorts have resulted in a reduction of mortality of women with this malignancy. However, beside this progress in dealing with breast cancer, there is still a 22% mortality rate in the USA, and higher rates of 30 ± 35% in other industrialized countries have been reported (Ferlay et al., 2001) . Thus, development of new strategies for prevention and treatment of breast cancer is still an important goal to be achieved. For this, a better understanding of the molecular events associated with the disease and their relationship to tumor progression would be essential.
Choline kinase (ChoK) is the enzyme responsible for the generation of phosphorylcholine (PCho) a metabolite that is involved in metabolic processes as well as in cell proliferation (Lacal, 2001; Smith et al., 1993) . ChoK and its product PCho have recently been involved in transformation mediated by human oncogenes (HernaÂ ndez-Alcoceba et al., 1997). Furthermore, a family of ChoK inhibitors have been proven to show antitumoral activity both in vitro and in vivo against human xenografts (HernaÂ ndez-Alcoceba et al., 1999) . The relevance of ChoK regulation in human carcinogenesis has not been properly addressed yet. Here, we have investigated the putative involvement of ChoK in human breast carcinomas. Our results suggest that indeed ChoK may contribute to the development of human breast carcinomas. A clear association of ChoK activity and the grade of the disease is reported. The potential use of this ®nding for breast cancer treatment is discussed.
Results

Increased ChoK activity in tumoral tissues of patients with breast cancer
We investigated the involvement of ChoK in breast cancer. To that end, normal and tumoral tissues from 39 dierent women with breast tumors were assayed for ChoK activity (Figure 1a) . Distribution of the values for all normal samples demonstrated a typical Gauss curve (Figure 1b ) with a mean value of 23.7 pmol PCho/mg protein/min and a standard deviation of +20.0 pmol PCho/mg protein/min. Distribution of the tumoral samples showed a wide Gauss curve, with a mean value of 289.4 pmol PCho/mg protein/min and a standard deviation of +297.8 pmol PCho/mg protein/min. As shown in Figure 1b , in addition to an increased mean value, elevated levels of ChoK activity were observed in a large proportion of tumoral tissues compared to the values from normal samples. In order to quantitate these dierences, an arbitrary cut-o for normal values of 200 pmol PCho/ mg protein/min was established. This arbitrary value was chosen since it provides 100% speci®city and 85% sensitivity, according to the ROC methodology (McNeil and Hanley, 1984) . Under these conditions, 15 (38.5%) of the tumor samples analysed scored positive for increased ChoK activity. Thus, a signi®-cant percentage of breast carcinomas has elevated ChoK activity when compared to normal tissues, suggesting a putative association of ChoK disregulation and the carcinogenic process in breast tumors.
ChoK activity and clinical features of breast carcinomas
To establish whether there was any relationship between ChoK activation and clinical features of breast cancer, the analysis of some pathologic parameters was performed. No signi®cant correlation was found regarding age, tumor size, progesterone receptors, vascular invasion, histologic type or p53, erbB-2 and Ki67 expression (Table 1) . A correlation between increased ChoK activity and high histologic grade (P50.001) was found ( Figure 2) . Finally, the lack of estrogen receptors (ER-negative) was also associated with ChoK activation (Table 1) . Thus, activation of ChoK could be considered as a marker of malignancy in breast tumors with a clear association with the histologic grade and the lack of estrogen receptors.
ChoK is overexpressed in patients with breast cancer
ChoK is activated with a high incidence in breast tumors. Up-regulation of ChoK could result from a speci®c increase in the expression of the enzyme by transcriptional regulation. Alternatively it could be a consequence of post-translational regulation. We next investigated these two possibilities and compared ChoK activity with increased levels of the enzyme. Analysis of ChoK expression of Western blot in normal and tumoral tissues from 53 patients was carried out using a polyclonal antibody raised against the partially puri®ed recombinant human ChoK protein. As an example of this kind of analysis. Figure  3 shows a prominent band readily observed in some of the tumor samples. A total of nine out of 53 (17%) of the tumor samples showed increased expression of the enzyme versus none of their normal counterparts. Furthermore, all normal tissues showed very similar basal levels of the enzyme that under similar conditions were almost undetectable (Figure 3 ). Further analysis showed that overexpression of ChoK was observed in tumoral tissues that also display increased ChoK activity (Table 1) , with a 100% correlation (P50.001). Since ChoK activity was increased in 38.5% of the samples, these results indicate the existence of dierent mechanisms for ChoK disregulation after malignant transformation, control of transcriptional levels and enzymatic regulation.
ChoK overexpression correlates with high histologic grade and ER-negative breast carcinoma
We next compared ChoK overexpression with the clinical parameters. No signi®cant correlation was found with age, tumor size, progesterone receptors, vascular invasion, histologic type or p53, erbB-2 and Ki67 expression (Table 2) . From the initial 53 samples analysed for ChoK expression by Western blot, all were suitable for further characterization versus histologic grade. Out of these, 14 were Grade I tumors, and none showed increased levels of ChoK when compared to those of normal tissues. By contrast, Grade II and III tumors, showed increased ChoK levels, with statistical signi®cance (P=0.017). Finally, a statistically signi®cant correlation was also found between ChoK overexpression and ER-negative breast carcinomas (P=0.003). From a total of 52 samples suitable for this analysis, 40 were positive for estrogen receptors. Three of them (7.5%) displayed increased levels of ChoK expression. The remaining 12 samples were ER-negative, and 50% of them showed increased levels of the enzyme (Table 2) . Thus, overexpression of the ChoK enzyme was found to be associated with more malignant tumors with an ERnegative expression pro®le.
Discussion
Cancer research has provided, more than ever, new modalities of treatment. A more ecient earlier detection of the tumors, a much better molecular characterization, as well as the discovery of novel drugs and proper combinations of treatments with proven ecacy has had an impact in overall survival rates. However, breast cancer patients are yet in need of alternative therapies since there is still a 22 ± 35% mortality rate in developed countries (Ferlay et al., 2001 ).
Here we provide evidence that ChoK activation is a frequent event associated to the carcinogenic process in breast cancer. This statement is based on our ®nding that 38.5% of the tumor samples analysed displayed a signi®cant increase in ChoK activity compared to the correspondent normal tissues. This compares favorably to those of other established tumor markers for breast cancer such as p53 (16 ± 34%), erbB-2 (20 ± 30%), and Bcl-2 (38%) (Thor et al., 1992; Tripathy and Benz, 1992; Olopade et al., 1997) . Finally, a clear relationship of ChoK activation with the grade of the disease is also reported, suggesting that ChoK disregulation might be associated with poor prognosis or greater malignancy.
Our results also indicate that those tumors with the highest ChoK activity had also overexpression of the enzyme, determined by Western blot. However, a substantial amount of tumor samples (20.5%) showed The primary treatment for breast cancer is surgery. Systemic adjuvant therapies are designed to eliminate cancer cells that metastasized from the primary tumor. The latter includes both chemotherapy and hormone therapy, based on the speci®c characteristics of each type of tumor. Thus, the requirement of an appropriate treatment for each case needs to be developed. Overexpression of the growth factor receptor erbB-2 is found in 20 ± 30% of breast tumors (Bonilla et al., 2001; Salazar et al., 2001; Tripathy and Benz, 1992) , and is regarded as an important factor for tumor prognosis. A large eort has been devoted to design speci®c molecules that interfere with erbB-2 signaling, both at the level of interfering with its ability to interact with its ligand, as well as blocking its tyrosine kinase activity (Kumar et al., 2000) . Antibody therapy has proven to be ecient only in 20 ± 25% of erbB-2-overexpressing tumors (Bonilla et al., 2001; Salazar et al., 2001 ). Our ®ndings demonstrate that ChoK activity is increased in 38.5% of the tumors, a higher rate than erbB-2, a well-established tumor marker for breast cancer. The correlation of ChoK activity and overexpression of the enzyme with more malignant tumors also suggest some prognostic value which may be comparable to that described for erbB-2 overexpression.
Estrogen and progesterone, besides playing a crucial role in many physiological processes, are involved in the development and progression of breast cancer. As a consequence, selective estrogen receptor modulators (SERMs) have acquired great impact because of their ability to modulate the proliferative eects of estrogen that are mediated through the estrogen receptor (ER). Our ®ndings demonstrate a strong association between ChoK activation and ER-negative breast carcinomas. Thus, 50% of ER-negative tumors overexpressed ChoK and 75% of them had increased ChoK activity. Finally 100% of the tumors with increased ChoK expression also showed increased ChoK activity.
Thus, as a potential clinical application, ChoK levels and activity could be useful to screen for high risk breast cancer groups, and help to determine the prognosis of a cancer patient.
These results may also have important consequences regarding treatment of breast cancer patients. Agents such as tamoxifen and raloxifen have shown to be able to decrease the incidence of breast cancer in high-risk women. This eect is due to a dramatic reduction in the incidence of ER-positive tumors, while the incidence of ER-negative tumors is unaected by the use of the drugs (Fentiman, 2000; Osborne, 1998; Powles et al., 1998) . Tamoxifen also reduces the recurrence rate of patients with operable breast cancer when it is given after surgery, but it is clear now that this eect is more evident in patients with ER-positive tumors (Osborne, 1998) . Thus, novel agents are needed to provide ecient broad-spectrum chemopreventive therapy, especially to healthy women at high risk for breast cancer as well as adjuvant treatments for patients with ER-negative tumors.
We have recently demonstrated the antitumor activity of ChoK inhibition both in vitro and in vivo (HernaÂ ndez-Alcoceba et al., 1997 . Hence, our study gives additional support for the importance of a new strategy that may be ecient for breast cancer patients. Both ER-positive and ER-negative breast cancer patients could bene®t from this new drugs since 29% of ER-positive tumors and 75% of ER-negative tumors has increased ChoK activity.
Materials and methods
Patients and clinical parameters analysed
Normal and tumoral tissues were extracted from a total of 53 patients with breast carcinomas, according to the precepts established by the Helsinki Declaration. Ages of patients oscilate between 29 and 91-years-old. Samples were analysed for ChoK expression levels by Western blotting, and when available, for further analysis of ChoK activity. The following parameters were compared to ChoK activity: age, tumor size, histologic grade, pathologic stage, estrogen and progesterone receptors, vascular invasion, lymph node metastases, pathologic stage and histologic type of tumor, p53, erbB-2 expression and Ki67. Tumor size, lymph node metastases and stage were assessed using the TNM classi®cation. Tumors were graded according to the Bloom ± Richardson grading system (Dominguez et al., 2000) . Steroid receptor content was determined by an immunohistochemical procedure, the results of which were considered to be positive when 25% or more of the cells stained positively. p53, erbB-2 and Ki67 were determined as previously described (Schneider et al., 2000) .
Lysis of human tissues
Tissues were collected during the duration of the studies from surgical biopsies. Samples were homogenized and lyzed in buer containing 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.3 M NaCl, 25 mM HEPES, pH 7.5, 20 mM b Glycerophosphate and 0.1% Triton X-100.
Assay for ChoK activity
ChoK essays were performed from homogenized tissues as described above as source of ChoK in buer containing 100 mM Tris-HCl pH 8.0, 100 mM MgCl 2 and 10 mM ATP. Physiological ChoK concentration (200 mM) was used as substrate in the presence of methyl[ 14 C]-choline chloride (50 ± 60 Ci/mmol, Amersham International). Reactions were performed at 37ëC for 30 min and stopped with ice-cold trichloracetic acid (TCA) at a ®nal concentration of 16%. Hydrophylic derivatives of choline (i.e. choline, phosphorylcholine), were resolved by thin layer chromatography (TLC) plates (60 A silica gel, Whatman, Clifton, NJ, USA) using as liquid phase 0.9% NaCl: methanol: ammonium hydroxide (50:75:5; v/v/v) . Radioactivity corresponding to PCho was automatically quanti®ed by an electronic radiography system (Instantimager; Packard, Meriden, CT, USA)
Analysis of ChoK expression by Western blot
Equal amounts of the dierent tissue lysates (30 mg) were boiled at 958C for 5 min in SDS ± PAGE sample buer. For Western blot analysis, proteins were electrophoresed onto 10% SDS ± PAGE gels poured in 20620 cm glass plates. Resolved proteins were transferred to nitro-cellulose, and blots were blocked for 2 h in 5% non-fat dried milk in T-TBS (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween 20). Blots were washed in T-TBS, and incubated for 1 h with an anti-ChoK antiserum obtained as previously described (RamõÂ rez de Molina et al., 2002) and then developed by ECL as described by the manufactures (Amersham). As loading control, blots were assayed against a-tubulin (T9026 from Sigma).
Statistical analysis
Normal values for ChoK were established by the ROC methodology (6c). Accordingly, abnormal ChoK activity levels were considered over 200 pmol PCho/mg protein/min which provided 100% speci®city and 85% sensitivity. The univariate associations between the presence or absence of ChoK alterations and baseline prognostic factors were analysed with a Fisher exact test for categorical variables and likelihood ratio test. All factors were treated as single categorical variables, with the exception of age at diagnosis and ChoK activity, which were analysed as continuous variables. All reported P-values are two-sided. Statistical signi®cance was de®ned as P50.05. Continuous variables with non-normal distribution were compared by means of the Kruskal Wallis test. All calculations were performed using SPSS software, version 10.
